Research is at the core of cancer interception. The Texas Cancer Interception Institute supports studies that move discoveries into real‑world care—helping improve how cancer is identified, monitored and treated.
Texas Cancer Interception Institute providers are committed to research that makes a tangible impact on the lives of people everywhere. Through the Multi-Cancer Early Detection (MCED), single-cancer diagnostic blood testing and Minimal Residual Disease (MRD) programs, the institute is studying how advanced blood-based testing may help identify cancer earlier, guide follow-up care and support more personalized monitoring after treatment.
The Multi‑Cancer Early Detection (MCED) Program is a large‑scale research initiative focused on understanding how blood‑based cancer screening may be used safely and effectively across a large health system. By combining advanced testing with digital tools, including smartphone technology, the program helps people participate while staying connected to care teams.
With tens of thousands of MCED tests and additional single‑cancer diagnostic and post‑operative monitoring tests administered across North Texas, researchers can study more than clinical results alone. The program also examines the person’s experience and what happens next after testing—how people move through follow‑up, diagnosis and care. Together, these insights generate real‑world evidence that helps inform the next generation of cancer detection tools and how they may be thoughtfully integrated into clinical care.
TCII’s integration with the Texas Immuno‑Oncology Biorepository (TIOB) gives researchers access to a large, long‑term collection of biospecimens paired with well‑documented clinical data. Together, these resources help to deepen understanding of how cancer develops and responds to treatment—supporting research that can inform more personalized, effective approaches to care over time. To learn more, visit: ClinicalTrials.gov (NCT#05371756)
At the Texas Cancer Interception Institute, research is designed to detect cancer earlier than ever before.. Through Baylor Scott & White Health, one of the nation’s largest networks of Commission on Cancer-accredited centers, those benefits extend across a connected network serving millions each year.
As one of the largest health systems in the United States, with 1,300 care sites, 7,000+ physicians and 59,000+ employees, 1 in 10 Texans receive care at Baylor Scott & White. At this scale, research isn’t confined to a single location or patient population; rather, it is studied, refined and applied across a broad community in real-world care settings.
The result is research that can move faster from insight to impact. Learnings from the Texas Cancer Interception Institute are not limited to a single site or population; rather, they help inform how earlier cancer detection can help people everywhere.
Research is at the core of cancer interception. Learn more about the studies, trials and research shaping the future of the fight against cancer and expanding what’s possible for people everywhere.
The Texas Cancer Interception Institute Command Center serves as a technology‑driven operations hub that brings together data, expertise and advanced analytics to support earlier cancer detection. By using artificial intelligence and machine learning, the Command Center helps identify patterns and insights that may not be visible through traditional approaches alone.
Digital pathology transforms traditional microscope slides into high‑resolution whole‑slide images that can be viewed and shared across care teams. This approach supports remote consultations, helps improve diagnostic accuracy and allows specialists to collaborate more easily—no matter where they are.
Radiomics uses advanced image analysis to uncover details in medical imaging that may not be visible to the human eye. By studying these subtle patterns, researchers can gain deeper insight into how tumors behave and respond to treatment.
A multitude of Liquid Biopsy (LBX) programs are underway, such as Multi-Cancer Early Detection (MCED), Single Cancer Early Detection (SCED) and Minimal Residual Disease (MRD) tests across a wide range of tumors to assess clinical validation, clinical performance and the implementation of these new assays in routine care.
The Texas Immuno‑Oncology Biorepository (TIOB) provides researchers with access to high‑quality biospecimens collected over time, paired with detailed clinical information, to better understand how cancer develops and how it responds to treatment.
By studying health trends across diverse populations, we can identify risk factors, improve access to screenings, create virtual cancer journeys on the MyBSWHealth app and tailor prevention strategies to reach more people—especially those in underserved communities.
